文献速递肝病消化道肿瘤与早癌

早期肝细胞癌患者的死亡原因分析

Causes of mortality among patients with early-stage hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2025-07-22

该回顾性队列研究纳入4个美国医疗系统2008至2022年间1336例早期肝细胞癌(BCLC 0/A期)患者,中位随访32.4个月,598例(44.8%)死亡,其中220例(37%)为肝癌相关死亡、114例(19%)为肝病相关非肝癌死亡、179例(30%)为其他原因死亡。根治性治疗与肝癌相关死亡(HR 0.34;95%CI 0.23-0.48)及肝病相关死亡(HR 0.23;95%CI 0.14-0.38)降低相关。

要点

  • 早期肝癌患者中肝癌相关死亡仍是最常见死因,占死亡者的37%。
  • 根治性治疗与肝癌相关死亡(HR 0.34)及肝病相关死亡(HR 0.23)降低相关。
  • AFP>20 ng/mL(HR 2.19)和肿瘤直径>3 cm(HR 1.69)为肝癌相关死亡的预测因素。

核心结论

  • 早期肝癌患者的死因构成多样,但肝癌相关死亡仍是最常见原因。
  • 需要努力优化早期肝癌患者根治性治疗的效果,以降低癌症相关死亡率。

研究设计与样本

  • 回顾性队列研究,纳入2008至2022年间4个美国医疗系统的早期肝细胞癌(BCLC 0/A期)患者1336例。
  • 采用多变量分析和Fine-Gray分析,以肝移植作为竞争结局,识别与死亡相关的因素。

主要发现

  • 1336例早期肝癌患者中,598例(44.8%)在中位随访32.4个月内死亡,其中220例(37%)为肝癌相关死亡、114例(19%)为肝病相关死亡、179例(30%)为其他原因死亡。
  • 肝癌相关、肝病相关和其他原因死亡的中位时间相似,分别为24个月(95%CI 22-31)、19个月(95%CI 15-23)和23个月(95%CI 19-27)。
  • 根治性治疗与肝癌相关死亡降低相关(HR 0.34;95%CI 0.23-0.48),与肝病相关死亡降低相关(HR 0.23;95%CI 0.14-0.38)。
  • 肝癌相关死亡的预测因素包括AFP>20 ng/mL(HR 2.19;95%CI 1.59-3.03)和肿瘤直径>3 cm(HR 1.69;95%CI 1.20-2.37)。
  • 肝病相关死亡与MASLD病因(HR 1.99;95%CI 1.09-3.65)、Child-Pugh B级肝硬化(HR 2.64;95%CI 1.58-4.42)和ALBI 2级(对比1级:HR 2.47;95%CI 1.21-5.06)相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Early detection of hepatocellular carcinoma (HCC) can reduce cancer-related mortality; however, there are often competing risks from comorbid conditions, including cirrhosis. Understanding causes of death among patients with early-stage HCC can inform strategies to improve surveillance effectiveness. APPROACH AND RESULTS: We conducted a retrospective cohort study of patients with early-stage HCC [Barcelona Clinic Liver Cancer (BCLC) stages 0/A] at 4 U.S. health systems between 2008 and 2022. We defined the primary cause of death as HCC-related, liver-related (non-HCC), and death from other causes. We used multivariable and Fine-Gray analysis, with liver transplant as a competing outcome, to identify factors associated with mortality. Among 1336 patients with early-stage HCC, 598 (44.8%) died during a median follow-up of 32.4 months-220 (37%) HCC-related, 114 (19%) liver-related, and 179 (30%) from other causes. Median time to death was similar between the groups: 24 (95% CI 22-31), 19 (95% CI 15-23), and 23 (95% CI 19-27) months for HCC-related, liver-related, and other causes of mortality, respectively. Curative treatment was associated with reduced HCC-related (HR 0.34; 95% CI 0.23-0.48) and liver-related mortality (HR 0.23; 95% CI 0.14-0.38). Predictors of HCC-related mortality included alpha-fetoprotein (AFP) >20 ng/mL (HR 2.19; 95% CI 1.59-3.03) and tumor diameter >3 cm (HR 1.69; 95% CI 1.20-2.37). Liver-related mortality was associated with MASLD (metabolic dysfunction-associated steatotic liver disease) etiology (HR 1.99; 95% CI 1.09-3.65), Child-Pugh B cirrhosis (HR 2.64; 95% CI 1.58-4.42), and Albumin-Bilirubin (ALBI) grade 2 (vs. grade 1: HR 2.47; 95% CI 1.21-5.06). CONCLUSIONS: Cause of death varies among patients with early-stage HCC, although HCC-related death remains the most common cause. Efforts are needed to optimize curative treatment effectiveness among patients with early-stage HCC to reduce cancer-related mortality.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Seif El Dahan K, Daher D, Rich NE, et al. Causes of mortality among patients with early-stage hepatocellular carcinoma. Hepatology. 2025. PMID: 40694813. doi:10.1097/HEP.0000000000001471

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。